189 related articles for article (PubMed ID: 31872348)
1. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
[TBL] [Abstract][Full Text] [Related]
2. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
3. CDK9 inhibitors in acute myeloid leukemia.
Boffo S; Damato A; Alfano L; Giordano A
J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
5. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
7. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
8. Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.
Wu T; Yu B; Gong W; Zhang J; Yu S; Tian Y; Zhao T; Li Z; Wang J; Bian J
Eur J Med Chem; 2023 Nov; 259():115711. PubMed ID: 37572539
[TBL] [Abstract][Full Text] [Related]
9. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
[TBL] [Abstract][Full Text] [Related]
10. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
Fiskus W; Manshouri T; Birdwell C; Mill CP; Masarova L; Bose P; Kadia TM; Daver N; DiNardo CD; Borthakur G; Khoury JD; Verstovsek S; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):23. PubMed ID: 35102145
[No Abstract] [Full Text] [Related]
13. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
14. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
15. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
[TBL] [Abstract][Full Text] [Related]
16. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L; Daver N
Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
[TBL] [Abstract][Full Text] [Related]
18. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
19. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC
Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525
[TBL] [Abstract][Full Text] [Related]
20. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.
Li L; Han C; Yu X; Shen J; Cao Y
J Healthc Eng; 2022; 2022():2842066. PubMed ID: 35126914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
